

Consolidated Financial Statements for the Year Ended March 31, 2026
FY2026 (April 1, 2025 - March 31, 2026) [UNAUDITED]

May 13 2026

Company name: Takara Holdings Inc.
 Stock exchange listings: Tokyo Stock Exchange (PRIME section)
 Code number: 2531
 URL: <https://www.takara.co.jp/>
 Company representative: Mutsumi Kimura, President
 Contact: Masakazu Usami, Public Relations& Investor Relations Dept.
 TEL: (075)241-5124
 Annual statement filing date (as planned): Jun 25, 2026

- Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the year ended March 31, 2026 (April 1, 2025 - March 31, 2026)

(1) Consolidated operating results

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Year ended March 31, 2026		Year ended March 31, 2025	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	394,316	8.7	362,693	6.9
Operating income (loss)	17,076	(17.1)	20,597	(7.4)
Ordinary income (loss)	16,861	(24.0)	22,180	(5.0)
Net income (loss) attributable to owners of the parent	11,696	(27.8)	16,202	0.2
Net income (loss) per share (Yen)	60.52		82.98	
Fully diluted net income per share (Yen)	-		-	
Return on equity		4.6		6.8
Ordinary income to total assets ratio		3.4		4.8
Operating income to net sales ratio		4.3		5.7
Note: Comprehensive income (loss)	19,976	(23.1)	25,976	(31.0)
(Reference) Income (loss) from equity method investment	70		64	

(2) Consolidated financial position

	As of March 31, 2026	As of March 31, 2025
	(Millions of yen)	(Millions of yen)
Total assets	513,801	477,587
Net assets	310,937	300,903
Equity ratio (%)	50.5	51.3
Net assets per share (Yen)	1,344.61	1,255.93
(Reference) Equity	259,339	245,228

(3) Consolidated Cash flow

	Year ended March 31, 2026	Year ended March 31, 2025
	(Millions of yen)	(Millions of yen)
Cash flow from operating activities	17,318	16,155
Cash flow from investing activities	(15,341)	(41,562)
Cash flow from financing activities	(9,307)	6,548
Cash and cash equivalents, end of year	69,125	75,280

2. Dividends

	Dividend per share (Yen)		
	Year ended March 31, 2025	Year ended March 31, 2026	Year ending March 31, 2027 (Forecast)
First quarter end	-	-	-
Second quarter end	-	-	-
Third quarter end	-	-	-
Year end	31.00	31.00	31.00
Annual	31.00	31.00	31.00
Total dividend (Millions of yen)	6,052	5,979	
Payout ratio (%)	37.4	51.2	50.2
Dividend on equity (%)	2.6	2.4	

Note: The year-end dividend for FY2026 included a 100th anniversary commemorative dividend of ¥2.00

3. Forecast for the year ending March 31, 2027(April 1, 2026- March 31, 2027)

Note: Percentages indicated changes from the same period of the previous fiscal year.

	Six months ending September 30, 2026		Year ending March 31, 2027	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	205,000	9.9	420,000	6.5
Operating income (loss)	8,800	13.0	18,800	10.1
Ordinary income (loss)	7,800	5.6	17,000	0.8
Net income (loss) attributable to owners of the parent	5,900	3.6	11,900	1.7
Net income per share (Yen)	30.59		61.70	

4. Others

(1) Material changes in subsidiaries during this period

(Changes in specified subsidiaries that caused a change in the scope of consolidation): Yes

Newly included: 1 (Name) Curio Bioscience, Inc.

(2) Changes in accounting policies, accounting estimates and retrospective restatement

1) Changes based on revisions of accounting standard: No

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

(3) Number of outstanding shares (common stock)

1) Number of outstanding shares at year end (Treasury stocks are included):

As of March 31, 2026 197,252,043 shares

As of March 31, 2025 197,252,043 shares

2) Number of treasury stocks at year end:

As of March 31, 2026 4,378,256shares

As of March 31, 2025 1,996,109shares

3) Average number of outstanding shares:

Year ended March 31, 2026 193,277,739shares

Year ended March 31, 2025 195,256,213 shares

- * Review of the Japanese-language originals of the attached consolidated financial statements by certified public accountants or an audit firm: No

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

* Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Holdings Inc. (the “Company”) Based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to “1. Overview of Financial Results for the ended March 31, 2026 Explanation of Consolidated Financial Forecasts and Other Forward-looking Statements” on page 5 of the attached document.